<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612192</url>
  </required_header>
  <id_info>
    <org_study_id>7348</org_study_id>
    <nct_id>NCT04612192</nct_id>
  </id_info>
  <brief_title>Light Therapy for Chronic Insomnia in General Practice</brief_title>
  <acronym>Insolux</acronym>
  <official_title>Light Therapy for Chronic Insomnia in General Practice: a Randomized Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Sleep disorders, especially insomnia&#xD;
&#xD;
        -  Attention deficits (or disorders), daytime somnolence and drug dependence&#xD;
&#xD;
        -  The goal is to evaluate whether light therapy could be used as an efficient alternative&#xD;
           treatment with direct application in general practice&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insomnia affects 15 to 20% of the general French adult population and increases with age.&#xD;
      General practitioners (GPs) are the first confronted to sleep disorders, especially insomnia.&#xD;
&#xD;
      Cognitive-behavioral therapies (CBT) have proven effective, but their implementation in&#xD;
      everyday practice is limited, and alternative treatments are still needed.&#xD;
&#xD;
      Light not only has a great influence on the sleep-wake cycle and alertness, but also on mood&#xD;
      and cognitive functions.&#xD;
&#xD;
      The administration time of light condition will be calculated for each individual in a&#xD;
      modality that has no impact on the circadian phase.&#xD;
&#xD;
      Study will be conduct on an outpatient basis in general practice&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of sleep efficiency between active and placebo light condition</measure>
    <time_frame>Before light therapy</time_frame>
    <description>ratio of total sleep time on total time in bed in measured with actimetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference of sleep efficiency between active and placebo light condition</measure>
    <time_frame>After 4 weeks of light therapy</time_frame>
    <description>ratio of total sleep time on total time in bed measured with actimetry</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Insomnia Chronic</condition>
  <condition>Sleep Disorder</condition>
  <condition>Circadian Rhythm Disorders</condition>
  <arm_group>
    <arm_group_label>Active light</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active blue-enriched bright light</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo light</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dim red placebo light</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active luminette</intervention_name>
    <description>receive an active blue-enriched light-glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period</description>
    <arm_group_label>Active light</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo luminette</intervention_name>
    <description>receive a dim red-light placebo light (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group</description>
    <arm_group_label>Placebo light</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Complaining of chronic insomnia according to ICSD-3 (International Classification of&#xD;
             Sleep Disorders) criteria and/or taking hypnotics at least 3 nights per week for more&#xD;
             than 3 months.&#xD;
&#xD;
          -  Non-hypnotic medication: stable medication during one month preceding the inclusion&#xD;
             and for the 8 weeks of the study.&#xD;
&#xD;
          -  Compliance with the treatment: the patient is able to have light therapy during the&#xD;
             required time and at the agreed schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe psychiatric disorder (severe major depression, schizophrenia, bipolar&#xD;
             disorder), obvious acute psychiatric comorbidity.&#xD;
&#xD;
          -  Untreated intrinsic sleep pathology: sleep apnea syndrome based on clinical criteria:&#xD;
             Berlin questionnaire score, restless legs syndrome manifesting more than 2 times a&#xD;
             week and/or requiring treatment.&#xD;
&#xD;
          -  Mild to severe dementia.&#xD;
&#xD;
          -  Neurodegenerative sleep troubles&#xD;
&#xD;
          -  Severe intercurrent pathology.&#xD;
&#xD;
          -  Ophthalmic troubles presenting a contraindication to light therapy: retinopathy,&#xD;
             age-related macular degeneration, diabetic retinopathy, macular hole, epiretinal&#xD;
             membrane); lens opacifications (cataract) justifying surgery (correction of poor&#xD;
             visual acuity, visual discomfort); glaucomatous and non-glaucomatous optic neuropathy&#xD;
             resulting in visual impairement.&#xD;
&#xD;
          -  Toxicomania, chronic alcoholism.&#xD;
&#xD;
          -  Secondary insomnia linked to somatic non-stabilized pathology.&#xD;
&#xD;
          -  Elements influencing circadian rhythm&#xD;
&#xD;
          -  Pregnancy, breastfeeding.&#xD;
&#xD;
          -  Participation in another interventional clinical trial which includes an exclusion&#xD;
             period&#xD;
&#xD;
          -  No information could be given to the patient (subject faces emergency situation,&#xD;
             comprehension difficulties, etc.)&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Non hypnotic treatment potentially inducing a level 3 sleepiness one week before&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>randomisation by sex</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juliette CHAMBE, MD</last_name>
    <phone>(0)3 88 79 08 02</phone>
    <phone_ext>+33</phone_ext>
    <email>juliette.chambe@unistra.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabien ROUGERIE, MD</last_name>
    <phone>(0)3 88 80 00 73</phone>
    <phone_ext>+33</phone_ext>
    <email>frougerie@unistra.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44210</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cédric RAT, MD</last_name>
      <email>Cedric.Rat@univ-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Aline HURTAUD, MD</last_name>
      <email>aline.hurtaud@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Juliette CHAMBE, MD</last_name>
      <email>Juliette.chambe@unistra.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eve RENAUD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Chronobiology Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

